Impact of the hepatoselective glucokinase activator <scp>TTP399</scp> on ketoacidosis during insulin withdrawal in people with type 1 diabetes

20229 citationsJournal Articlegreen Open Access

Authors

Klara R. Klein · University of North Carolina at Chapel Hill

Schafer Boeder · University of California, San Diego

Jennifer L. R. Freeman · vTv Therapeutics (United States)

Imogene Dunn · vTv Therapeutics (United States)

Chris Dvergsten · vTv Therapeutics (United States)

Supradeep S. Madduri · University of North Carolina at Chapel Hill

Erin R. Giovannetti

Abstract

When used as an adjunctive therapy to insulin, TTP399 improves glycaemia without increasing hypoglycaemia in individuals with T1D. During acute insulin withdrawal, TTP399 did not increase BHB concentrations and decreased the incidence of DKA.

Topics & Keywords

Pancreatic function and diabetes Diabetes Management and Research Diabetes and associated disorders

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Diabetes Obesity and Metabolism

Volume 24, Issue 8, pp. 1439-1447

DOI: 10.1111/dom.14697

Field-Weighted Citation Impact: 1.94